title: Synthesis and ligand binding of tropane ring analogues of paroxetine.
abstract: (3S,4R)-4-(4-Fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl] piperidine [(3S,9R)-3, paroxetine] is a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant in humans. In previous studies, we reported that certain (1R)-3 beta-(substituted phenyl)nortropane-2 beta-carboxylic acid methyl esters (2a) exhibited high affinity and reasonable selectivity for the serotonin transporter (5-HTT). The major structural differences between 2a and (3S,4R)-3 are that 2a possesses a different absolute stereochemistry and has an ethylene bridge not present in 3. In addition, 2a possesses a carbomethoxy substituent adjacent to the aryl ring, whereas (3S,4R)-3 contains a [3,4-(methylenedioxy)phenoxy]methyl group. In this study, we present the synthesis and biological evaluations of six of the possible eight isomers of 3-(4-fluorophenyl)-2-[[3,4-(methylenedioxy)phenoxy]methyl]nortropane+ ++ (4). The data for inhibition of [3H]paroxetine binding show that (1R)-2 beta, 3 alpha-4c, which has the same stereochemistry as paroxetine, has the highest affinity at the 5-HTT. Strikingly, the most potent compounds for inhibition of [3H]WIN-35,428 binding were not the (1R)-2 beta, 3 beta-isomers but rather (1R)-2 beta, 3 alpha-4c and (1S)-2 beta, 3 alpha-4f. Conformational analyses show that these isomers exist in a flattened boat conformation with pseudoequatorial substituents. Thus, the binding data show that this conformation is recognized by the DAT-associated binding site and also suggest that this conformation of paroxetine is recognized by the 5-HTT-associated binding site.
authors.affiliation: Research Triangle Institute, North Carolina 27709, USA.
authors.forename: K I
authors.initials: KI
authors.lastname: Keverline-Frantz
authors.forename: J W
authors.initials: JW
authors.lastname: Boja
authors.forename: M J
authors.initials: MJ
authors.lastname: Kuhar
authors.forename: P
authors.initials: P
authors.lastname: Abraham
authors.forename: J P
authors.initials: JP
authors.lastname: Burgess
authors.forename: A H
authors.initials: AH
authors.lastname: Lewin
authors.forename: F I
authors.initials: FI
authors.lastname: Carroll
mesh_terms: D001667:Binding, Competitive; D003042:Cocaine / Q000031:analogs & derivatives / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000378:metabolism; D007536:Isomerism; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008956:Models, Chemical; D008958:Models, Molecular; D017374:Paroxetine / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry* / Q000378:metabolism; D013329:Structure-Activity Relationship; D014326:Tropanes / Q000138:chemical synthesis* / Q000737:chemistry* / Q000378:metabolism
chemical_list: D003042:Cocaine; D018765:Dopamine Uptake Inhibitors; D008024:Ligands; D017374:Paroxetine; D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D014326:Tropanes; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester